Ataxia-telangiectasia: atypical presentation and toxicity of cancer treatment
- PMID: 19650357
- DOI: 10.1017/s0317167100007794
Ataxia-telangiectasia: atypical presentation and toxicity of cancer treatment
Abstract
Background: The onset of progressive cerebellar ataxia in early childhood is considered a key feature of ataxia-telangiectasia (A-T), accompanied by ocular apraxia, telangiectasias, immunodeficiency, cancer susceptibility and hypersensitivity to ionizing radiation.
Methods: We describe the clinical features and course of three Mennonite children who were diagnosed with A-T following the completion of therapy for lymphoid malignancies.
Results: Prior to cancer therapy, all had non-progressive atypical neurological abnormalities, with onset by age 30 months, including dysarthria, dyskinesia, hypotonia and/or dystonia, without telangiectasias. Cerebellar ataxia was noted in only one of the children and was mild until his death at age eight years. None had severe infections. All three children were "cured" of their lymphoid malignancies, but experienced severe adverse effects from the treatments administered. The two children who received cranial irradiation developed supratentorial primitive neuroectodermal tumors of the brain, an association not previously described, with fatal outcomes.
Conclusions: The range of neurological presentations of A-T is broad. Ataxia and telangiectasias may be minimal or absent and the course seemingly non-progressive. The diagnosis of A-T should be considered in all children with neuromotor dysfunction or peripheral neuropathy, particularly those who develop lymphoid malignancies. The consequences of missing the diagnosis may be dire. Radiation therapy and radiomimetic drugs should be avoided in individuals with A-T.
Similar articles
-
Acute lymphoblastic leukemia in early childhood as the presenting sign of ataxia-telangiectasia variant.Pediatr Hematol Oncol. 2013 Sep;30(6):574-82. doi: 10.3109/08880018.2013.777949. Epub 2013 Mar 19. Pediatr Hematol Oncol. 2013. PMID: 23509889 Clinical Trial.
-
New diagnosis of atypical ataxia-telangiectasia in a 17-year-old boy with T-cell acute lymphoblastic leukemia and a novel ATM mutation.J Hum Genet. 2017 Apr;62(5):581-584. doi: 10.1038/jhg.2017.6. Epub 2017 Jan 26. J Hum Genet. 2017. PMID: 28123174 Free PMC article.
-
[Clinical, biological and genetic study of 24 patients with ataxia telangiectasia from southern Tunisia].Rev Neurol (Paris). 2000 Jul;156(6-7):634-7. Rev Neurol (Paris). 2000. PMID: 10891797 Review. French.
-
Ophthalmic features of ataxia telangiectasia-like disorder.J AAPOS. 2008 Apr;12(2):186-9. doi: 10.1016/j.jaapos.2007.09.016. Epub 2007 Dec 21. J AAPOS. 2008. PMID: 18083591
-
[Pathogenesis, diagnosis, clinical and therapeutic aspects of ataxia telangiectasia].Klin Padiatr. 1997 Sep-Oct;209(5):328-35. doi: 10.1055/s-2008-1043972. Klin Padiatr. 1997. PMID: 9411043 Review. German.
Cited by
-
Successful Treatment of Large B-Cell Lymphoma in a Child with Compound Heterozygous Mutation in the ATM Gene.Int J Mol Sci. 2023 Jan 6;24(2):1099. doi: 10.3390/ijms24021099. Int J Mol Sci. 2023. PMID: 36674612 Free PMC article.
-
Spontaneous Regression of Diffuse Large B-cell Lymphoma in a Patient with Ataxia-Telangiectasia.Adv Biomed Res. 2022 Apr 29;11:31. doi: 10.4103/abr.abr_169_21. eCollection 2022. Adv Biomed Res. 2022. PMID: 35720220 Free PMC article.
-
Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders.Cancers (Basel). 2022 Apr 14;14(8):2000. doi: 10.3390/cancers14082000. Cancers (Basel). 2022. PMID: 35454905 Free PMC article. Review.
-
The natural history of ataxia-telangiectasia (A-T): A systematic review.PLoS One. 2022 Mar 15;17(3):e0264177. doi: 10.1371/journal.pone.0264177. eCollection 2022. PLoS One. 2022. PMID: 35290391 Free PMC article.
-
Atypical Ataxia Presentation in Variant Ataxia Telangiectasia: Iranian Case-Series and Review of the Literature.Front Immunol. 2022 Jan 14;12:779502. doi: 10.3389/fimmu.2021.779502. eCollection 2021. Front Immunol. 2022. PMID: 35095854 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Research Materials
Miscellaneous